These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 24499951)

  • 21. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals.
    Okwundu CI; Uthman OA; Okoromah CA
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007189. PubMed ID: 22786505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
    Rockstroh JK; DeJesus E; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Plummer A; Abram M; Cheng AK; Fordyce MW; Szwarcberg J;
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):483-6. PubMed ID: 23337366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
    Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
    N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis.
    Liegeon G; Antoni G; Pialoux G; Capitant C; Cotte L; Charreau I; Tremblay C; Cua E; Senneville E; Raffi F; Meyer L; Molina JM;
    J Int AIDS Soc; 2020 Feb; 23(2):e25420. PubMed ID: 32086878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
    Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
    Baeten JM; Donnell D; Ndase P; Mugo NR; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kakia A; Odoyo J; Mucunguzi A; Nakku-Joloba E; Twesigye R; Ngure K; Apaka C; Tamooh H; Gabona F; Mujugira A; Panteleeff D; Thomas KK; Kidoguchi L; Krows M; Revall J; Morrison S; Haugen H; Emmanuel-Ogier M; Ondrejcek L; Coombs RW; Frenkel L; Hendrix C; Bumpus NN; Bangsberg D; Haberer JE; Stevens WS; Lingappa JR; Celum C;
    N Engl J Med; 2012 Aug; 367(5):399-410. PubMed ID: 22784037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
    DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
    Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings.
    Myers GM; Mayer KH
    AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.
    Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
    HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
    Nishijima T; Gatanaga H; Shimbo T; Komatsu H; Endo T; Horiba M; Koga M; Naito T; Itoda I; Tei M; Fujii T; Takada K; Yamamoto M; Miyakawa T; Tanabe Y; Mitsuya H; Oka S;
    PLoS One; 2013; 8(8):e73639. PubMed ID: 23951362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.